Literature DB >> 63657

Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

S Moncada, E A Higgs, J R Vane.   

Abstract

Fresh rings of arteries and veins obtained from surgical specimens generated an unstable substance, prostacyclin (prostaglandinx, [P.G.X]) WHICH IS A POTENT INHIBITOR OF PLATELET AGGREGATION. The spontaneous generation of prostacyclin as well as its generation from exogenous arachidonic acid was inhibit by incubation of the tissues with a prostaglandin-synthetase inhibitor such as indomethacin, whilst the generation induced by prostaglandin endoperoxides was not. 15-Hydroperoxyarachidonic acid (a lipid hydroperoxide) inhibited the generation of prostacyclin in all three situations. It is postulated that prostacyclin is important for prevention of deposition of platelets on the vessel wall and that the inhibition or prevention of the generation of prostacyclin is important in the genesis of diseases, especially those in which increased lipid peroxidation occurs, such as atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 63657     DOI: 10.1016/s0140-6736(77)91655-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  140 in total

1.  Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin.

Authors:  J W Burch; N L Baenziger; N Stanford; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

2.  Prostacyclin concentrations in haemolytic uraemic syndrome after acute shigellosis.

Authors:  R S Heyderman; N J Klein
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

3.  Relation between fibrinolytic activity and prostacyclin generation of atherosclerotic artery and dacron prosthetic graft.

Authors:  H Sinzinger; K Silberbauer; M Winter; W Auerswald
Journal:  Experientia       Date:  1979-06-15

Review 4.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

Authors:  Tilo Grosser; Susanne Fries; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

Review 5.  Adventures in vascular biology: a tale of two mediators.

Authors:  S Moncada
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-05-29       Impact factor: 6.237

6.  Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation.

Authors:  R Brandt; A Dembińska-Kieć; R Korbut; R J Gryglewski; J Nowak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

7.  Plasma factors influencing PGI2-like activity in patients with IgA nephropathy and Henoch-Schönlein purpura.

Authors:  S Túri; J Nagy; I Haszon; Z Havass; M Németh; C Bereczki
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

8.  Intimal thickening in autogenous vein grafts in rabbits: influence of aspirin and dipyridamole.

Authors:  A J Murday; A H Gershlick; Y D Syndercombe-Court; P G Mills; C T Lewis
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

9.  The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man.

Authors:  S Hassan; H Pickles; A Fish; C Burke; S Warrington; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

Review 10.  Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.

Authors:  B Holmes; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.